Unique ID issued by UMIN | UMIN000058182 |
---|---|
Receipt number | R000066413 |
Scientific Title | A multicenter study on the significance of IGRA screening for the diagnosis of latent tuberculosis infection in patients initiating hemodialysis |
Date of disclosure of the study information | 2025/06/20 |
Last modified on | 2025/06/16 11:03:18 |
A multicenter study on the significance of IGRA screening for the diagnosis of latent tuberculosis infection in patients initiating hemodialysis
Latent tuberculosis infection in patients initiating hemodialysis
A multicenter study on the significance of IGRA screening for the diagnosis of latent tuberculosis infection in patients initiating hemodialysis
Latent tuberculosis infection in patients initiating hemodialysis
Japan |
Latent tuberculosis infection
Nephrology | Infectious disease |
Others
NO
To investigate the prevalence and characteristics of latent tuberculosis infection (LTBI) in patients initiating dialysis
Others
epidemiological study
Prevalence of latent tuberculosis infection (LTBI) in patients initiating hemodialysis
Observational
50 | years-old | <= |
90 | years-old | > |
Male and Female
[Hemodialysis Group]
Male and Female aged 50 to under 90 years who are newly initiated on hemodialysis and do not meet any exclusion criteria.
[Control Group]
Male and Female aged 50 to under 90 years who do not meet any exclusion criteria.
Exclusion Criteria:
These criteria specify reasonable grounds for excluding individuals from the study population who otherwise meet the inclusion criteria.
1) Individuals with a history of tuberculosis
2) Individuals who have previously received treatment for latent tuberculosis infection (LTBI)
3) Individuals with a household member diagnosed with active tuberculosis
4) Individuals in the control group with an estimated glomerular filtration rate (eGFR) <= 45 mL/min/1.73m2
5) Individuals in the control group who are receiving specialized outpatient care for kidney disease
6) Individuals in the hemodialysis group undergoing temporary dialysis initiation, such as continuous hemodiafiltration (CHDF)
800
1st name | Ayumi |
Middle name | |
Last name | Yoshifuji |
Keio University
School of Medicine, Department of Infectious Diseases
1608582
35 Shinanomachi, Shinjuku-ku, Tokyo
+81-3-3353-1211
jsdt.vaccine.antibody@gmail.com
1st name | Tomoki |
Middle name | |
Last name | Nagasaka |
Keio University
School of Medicine, Department of Infectious Diseases
1608582
35 Shinanomachi, Shinjuku-ku, Tokyo
+81-3-3353-1211
jsdt.vaccine.antibody@gmail.com
Keio University
Revvity Japan
Profit organization
Keio University School of Medicine Ethics Committee
35 Shinanomachi, Shinjuku-ku, Tokyo
+81-3-3353-1211
med-rinri-jimu@adst.keio.ac.jp
NO
2025 | Year | 06 | Month | 20 | Day |
Unpublished
Open public recruiting
2023 | Year | 08 | Month | 28 | Day |
2023 | Year | 10 | Month | 11 | Day |
2023 | Year | 10 | Month | 12 | Day |
2027 | Year | 03 | Month | 31 | Day |
Participants will provide blood samples for the evaluation of IGRA. Basic survey forms will be completed by the collaborating and cooperating research institutions to collect information on patient background, presence or absence of tuberculosis onset, and other relevant data.
2025 | Year | 06 | Month | 16 | Day |
2025 | Year | 06 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066413